nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2025, 08, v.47 73-80
高效液相色谱法同时测定布美他尼原料药中8种杂质含量
基金项目(Foundation):
邮箱(Email): 94147896@qq.com;
DOI: 10.13822/j.cnki.hxsj.2025.0053
摘要:

建立高效液相色谱法(HPLC-DAD)同时检测布美他尼原料药中的8种杂质含量。采用Thermo Hypersil GOLD C18(4.6 mm×250 mm, 5μm,孔径120?)为色谱柱,以0.1%(体积分数)三氟乙酸溶液(取1 mL三氟乙酸溶于1 000 mL水中)为流动相A,甲醇为流动相B,梯度洗脱(0~5 min 60%A;5~10 min 60%A→15%A;10~20 min 15%A;20~25 min 15%A→60%A;25~30 min 60%A),流速为1.0 mL/min,柱温为30℃,进样量为20μL。空白溶剂不干扰布美他尼及其8种杂质的测定,杂质A、B、C、D、E、G、I、J质量浓度分别在0.020 1~4.028 0、0.028 0~3.730 1、0.045 8~3.661 8、0.050 9~4.069 2、0.048 5~3.877 3、0.101 1~4.042 8、0.050 9~4.070 0和0.051 8~4.147 7μg/mL范围内与相应峰面积呈良好的线性关系,相关系数r分别为0.999 3、0.999 1、0.999 9、0.999 4、0.999 6、0.999 2、0.999 9、0.998 8,检测限(LOD)为7.05~35.37 ng/mL,定量限(LOQ)为20.14~101.07 ng/mL,杂质A、B、C、D、E、G、I、J的平均回收率分别为95.4%、93.0%、101.1%、98.7%、100.0%、101.0%、101.2%、98.1%,RSD分别为1.26%、0.63%、1.97%、0.40%、3.08%、0.79%、1.18%、0.85%。所建立的高效液相色谱法(HPLC)高效、稳健、准确,可同时测定布美他尼原料药中8种杂质(工艺杂质与降解产物)的含量。

Abstract:

A high-performance liquid chromatography method with diode-array detection(HPLC-DAD) was established for the simultaneous determination of eight impurities in bumetanide active pharmaceutical ingredient(API).A Thermo Hypersil GOLD C18(4.6 mm×250 mm, 5 μ m, pore size120 ?) was used, with 0.1% volume fraction trifluoroacetic acid solution(prepared by dissolving 1 mL trifluoroacetic acid in 1 000 mL water) as mobile phase A and methanol as mobile phase B.A gradient elution was employed(0~5 min 60% A;5~10 min 60% A→15% A;10~20 min 15% A;20~25 min 15% A→60% A;25~30 min 60% A).The flow rate was 1.0 mL/min, the column temperature was 30 ℃,and the injection volume was 20 μL.The blank solvent showed no interference with the detection of bumetanide or its eight impurities.The mass concentrations of impurities A,B,C,D,E,G,I,and J showed good linear relationships with their corresponding peak areas in the range of 0.020 1~4.028 0,0.028 0~3.730 1,0.045 8~3.661 8,0.050 9~4.069 2,0.048 5~3.877 3,0.101 1~4.042 8,0.050 9~4.070 0,and 0.051 8~4.147 7 μg/mL,respectively.The correlation coefficients r was 0.999 3,0.999 1,0.999 9,0.999 4,0.999 6,0.999 2,0.999 9,and 0.998 8.The limits of detection(LOD) ranged from 7.05 to 35.37 ng/mL,and the limits of quantification(LOQ) ranged from 20.14 to 101.07 ng/mL.The average recoveries of impurities A,B,C,D,E,G,I,and J were 95.4%,93.0%,101.1%,98.7%,100.0%,101.0%,101.2%,and 98.1%,respectively, with corresponding relative standard deviations(RSDs) of 1.26%,0.63%,1.97%,0.40%,3.08%,0.79%,1.18%,and 0.85%.The established HPLC method is efficient, robust and accurate, and is suitable for the simultaneous determination of eight impurities(both process-related impurities and degradation products) in bumetanide API.

参考文献

[1]L?scher W,Gramer M,R?mermann K.Biopharm.Drug Dispos.,2024,45(3):138-148.

[2]Ge Y Q,Ye X X,Le J,Yang Y J,Wang Y.J.Pharm.Anal.,2020,40(1):83-89.葛雨琦,叶晓霞,乐健,杨永健,王彦.药物分析杂志,2020,40(1):83-89.

[3]Schlingemann J,Burns M J,Ponting D J,Avila C M,Romero N E,Jaywant M A,Smith G F,Ashworth I W,Simon S,Saal C,Wilk A.J.Pharm.Sci.,2022,112(5):1 287-1 304.

[4]Shakleya D,Asmelash B,Alayoubi A,Abrigo N,Mohammad A,Wang J,Zhang J H,Yang J Y,Marzan T A,Li D,Shaklah M,Alsharif F M,Desai S,Faustino P J,Ashraf M,O′connor T,Vera M,Raw A,Sayeed V A,Keire D.J.Pharm.Sci.,2023,112(12):3 075-3 087.

[5]Wen H R,Huang Q,Han S Q,Jiang H,Qin C,Shi H K,Zhao T T,Geng X C,Wang Q.Chin.J.Pharm.,2024,21(3):307-312;318.文海若,黄勤,韩素芹,姜华,秦超,石皓琨,赵婷婷,耿兴超,汪祺.中国药物警戒,2024,21(3):307-312;318.

[6]Tian Y,Tao X S,Feng Y Y,Yao S C,Yin L H,Ning B M.Chin.J.Antibiot.,2024,49(1):13-25.田冶,陶晓莎,冯媛媛,姚尚辰,尹利辉,宁保明.中国抗生素杂志,2024,49(1):13-25.

[7]Peng S Y,Chen H,Yin J.Drug Eval.Res.,2022,45(12):2 583-2 590.彭诗雁,陈华,尹婕.药物评价研究,2022,45(12):2 583-2 590.

[8]Wan J Y,Chen H,Yin J.J.Pharm.Anal.,2022,42(4):557-571.万君玥,陈华,尹婕.药物分析杂志,2022,42(4):557-571.

[9]The United States Pharmacopeial Convention.United States Pharmacopeia-National Formulary 43rd Edition,Rockwell:The US Food and Drug Administration,2019.

[10]Chinese Pharmacopoeia Commission.Pharmacopoeia of the People′s Republic of China(2020 edition).2020 Edition Part 2 and Part 4.Beijing:China Medical Science and Technology Press,2020.国家药典委员会.中华人民共和国药典(2020年版),2020年版二部和四部.北京:中国医药科技出版社,2020.

[11]European Pharmacopoeia Committee.European Pharmacopoeia.EP11.0.Strasbourg:European Directorate for the Quality of Medicines & Health Care,2023.欧洲药典委员会.欧洲药典.EP11.0.斯特拉斯堡:欧洲药品质量管理局,2023.

[12]ICHQ3A(R2).Impurities in New Active Pharmaceutical Ingredients,2006-10-25.

[13]Zhao S J,Qu M M,Wang C X,Gong Y,Xu H,Liu C C,Xie J W.Chin.J.Pharmacol.Toxicol.,2023,37(3):229-240.赵舒婧,瞿敏敏,王朝霞,龚莹,徐华,刘翠翠,谢剑炜.中国药理学与毒理学杂志,2023,37(3):229-240.

[14]Liu N,Gu H,Li X,She C,Min Y H,Li S C.Phy.Test.Chem.Anal.B:Chem.Anal.,2023,59(8):930-936.刘娜,辜慧,李旭,佘城,闵宇航,李澍才.理化检验-化学分册,2023,59(8):930-936.

[15]Pan C,Meng P,Xu D M,Huang S L,Huang Y H,Cai X M,Chen N J.Chin.J.Anal.Lab.,2024,43(12):1 778-1 784.潘城,孟鹏,徐敦明,黄姝玲,黄永辉,蔡小明,陈宁静.分析试验室,2024,43(12):1 778-1 784.

[16]Wang R Y,Si F F,Chen Q J,Ren Y P.Phy.Test.Chem.Anal.B:Chem.Anal.,2023,59(8):948-952.王荣艳,斯菲菲,陈青俊,任一平.理化检验-化学分册,2023,59(8):948-952.

基本信息:

DOI:10.13822/j.cnki.hxsj.2025.0053

中图分类号:O657.72;TQ460.72

引用信息:

[1]叶红兵,张蒙蒙,夏宇航,等.高效液相色谱法同时测定布美他尼原料药中8种杂质含量[J].化学试剂,2025,47(08):73-80.DOI:10.13822/j.cnki.hxsj.2025.0053.

投稿时间:

2025-03-19

投稿日期(年):

2025

终审时间:

2025-05-14

终审日期(年):

2025

审稿周期(年):

1

发布时间:

2025-08-15

出版时间:

2025-08-15

检 索 高级检索